Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to its newly appointed chief executive officer, William Chou, M.D.
Related news for (PASG)
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights